[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100430177":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":60,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":25,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Ulm","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Immunoadsorption","EXPERIMENTAL","3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)",[13],"Device: Immunoadsorption",{"label":15,"type":16,"description":17,"interventionNames":18},"Immunoglobulins","ACTIVE_COMPARATOR","5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.",[19],"Biological: Immunoglobulins",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","see arm\u002Fgroup description",[9],null,{"type":27,"name":15,"description":23,"armGroupLabels":28,"otherNames":25},"BIOLOGICAL",[15],[30],{"name":31,"affiliation":5,"role":32},"Johannes Dorst, Prof","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","+49 731 177 5285","johannes.dorst@uni-ulm.de",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Department of Neurology, University of Ulm","RECRUITING","Ulm","Baden-Wurttemberg","89081","Germany","DE",{"type":48,"coordinates":49},"Point",[50,51],9.99155,48.39841,{"lat":51,"lon":50},[54,59],{"name":55,"role":35,"phone":56,"phoneExt":57,"email":58},"Albert C Ludolph, MD, Prof.","+49-731-177-","1200","albert.ludolph@rku.de",{"name":55,"role":32,"phone":25,"phoneExt":25,"email":25},{"type":32,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Albert Christian Ludolph, Prof.","Prof. Dr.",[64],{"name":65,"class":66},"Miltenyi Biomedicine GmbH","INDUSTRY","100430177","phase-2-immunoadsorption-versus-immunoglobulins-for-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-cidp-100430177",false,"NCT04881682","Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","IVITOC","Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines\n* Disease duration of 3 years or less\n* Age 18 years or above\n* Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician\n\nExclusion Criteria:\n\n* Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg\u002Fl, or evidence of nitrite-positive urinary tract infection\n* Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment\n* immunoglobulin A deficiency\n* Other contraindications against immunoadsorption or intravenous immunoglobulins","ALL","18 Years",{"count":77,"type":78},20,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).",[84],"CIDP","2026-04-30",{"date":87,"type":88},"2026-05-01","ACTUAL",{"date":90,"type":88},"2023-05-01",{"date":92,"type":78},"2028-03-01",{"name":5,"class":6},1]